These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 35597172)

  • 41. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Hu M; Zhong C; Wang J; Chen J; Zhou T
    Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting
    Liu H; Qin J; Qian X
    Cancer Control; 2024; 31():10732748241292782. PubMed ID: 39417568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study.
    Wu W; Yu S; Huang J; Qi Q; Wu Y; Dong J
    BMC Cancer; 2024 Aug; 24(1):1010. PubMed ID: 39143560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer.
    Yu C; Xu T; Fang H; Wang X; Liu N; Yang L; Fang S
    J Neurooncol; 2024 Aug; 169(1):203-213. PubMed ID: 38916849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients.
    Chen M; Xu Y; Zhao J; Liu X; Liu X; Zhang D; Shi Y; Zhang L; Zhong W; Wang M
    Clin Lung Cancer; 2023 May; 24(3):278-286. PubMed ID: 36635116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].
    Tian M; Wang N; Dou Z; Song X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2024 Aug; 27(8):579-592. PubMed ID: 39318251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.
    Liao YT; Wang LC; Sun RL; Yeh YC; Huang HC; Shen CI; Tseng YH; Hsiao TH; Chao HS; Luo YH; Chen YM; Chiang CL
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10365-10376. PubMed ID: 37277579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
    Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
    Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).
    Choi DH; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Lee SH
    Transl Lung Cancer Res; 2023 Dec; 12(12):2448-2459. PubMed ID: 38205202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
    Remon J; Hendriks LEL; Cardona AF; Besse B
    Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer.
    Seo D; Lim JH
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
    Shah V; McNatty A; Simpson L; Ofori H; Raheem F
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
    Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.
    Bazhenova L; Minchom A; Viteri S; Bauml JM; Ou SI; Gadgeel SM; Trigo JM; Backenroth D; Li T; Londhe A; Mahadevia P; Girard N
    Lung Cancer; 2021 Dec; 162():154-161. PubMed ID: 34818606
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
    Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
    Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
    Brazel D; Kroening G; Nagasaka M
    BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.